Rabbit Polyclonal LIPI Antibody

LIPI (Lipase I) antibodies are primarily associated with research targeting enzymes involved in lipid metabolism. LIPI, a member of the lipase family, plays a role in hydrolyzing lipids into free fatty acids and glycerol, influencing energy homeostasis and cellular signaling. Its expression has been linked to metabolic disorders, cancer, and immune regulation. In oncology, LIPI has emerged as a potential biomarker; for instance, the Lung Immune Prognostic Index (LIPI score) integrates peripheral immune and inflammatory markers to predict outcomes in lung cancer patients treated with immunotherapy. Antibodies against LIPI are critical tools for detecting protein expression in tissues or serum, enabling studies on its biological functions and clinical relevance. Recent research explores LIPI's role in tumor microenvironments, where altered lipid metabolism may promote immune evasion or therapeutic resistance. Additionally, LIPI antibodies have been utilized in autoimmune and metabolic disease models to investigate dysregulated lipid processing. Despite progress, the mechanistic pathways of LIPI remain partially understood, necessitating further validation of antibody specificity and functional studies. These antibodies hold promise for diagnostic applications and as therapeutic targets, particularly in cancers where lipid metabolism is reprogrammed. Ongoing studies aim to clarify LIPI's interplay with immune checkpoints and its potential as a companion biomarker for precision therapies.